,trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['trastuzumab', 'breast']
patients with her2-low #breastcancer may have a new treatment option, trastuzumab deruxtecan (t-dxd), according to a study led our dr. shanu modi, who will be presenting the findings in today's #asco22 plenary session. 
The official account of Memorial Sloan Kettering Cancer Center, the Sloan Kettering Institute, and Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences